SCHEMBL25755506

SCHEMBL25755506

CCOCCn1ncc2scc(Br)c2c1=O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.36
HTT P42858 1/20 0.36
NPC1 O15118 4/20 0.33
RAB9A P51151 4/20 0.33
SMN1; SMN2 Q16637 3/20 0.33
KDM4E B2RXH2 1/20 0.33
HSD17B10 Q99714 1/20 0.33
MITF O75030 2/20 0.31
S1PR4 O95977 1/20 0.31
MAPT P10636 1/20 0.31
S1PR1 P21453 1/20 0.31
KMT2A Q03164 1/20 0.31
LMNA P02545 1/20 0.31
ADORA2A P29274 2/20 0.31
ADORA2B P29275 2/20 0.31
PDE4A P27815 1/20 0.31
PDE4B Q07343 1/20 0.31
PDE4C Q08493 1/20 0.31
PDE4D Q08499 1/20 0.31
HCAR3 P49019 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25755264 0.86 NPC1 (0.36) ALDH1A1HTTNPC1RAB9ASMN1; SMN2
SCHEMBL25755170 0.82 KMT2A (0.38) ALDH1A1NPC1RAB9ASMN1; SMN2MITF
SCHEMBL18956246 0.77 MEN1 (0.46) ALDH1A1HTTNPC1RAB9ASMN1; SMN2
SCHEMBL25755439 0.74 GPR139 (0.38) ALDH1A1NPC1RAB9ASMN1; SMN2MITF
SCHEMBL22146264 0.73 NPC1 (0.33) ALDH1A1NPC1RAB9ASMN1; SMN2MITF
SCHEMBL27199398 0.72 PTGS2 (0.34) ALDH1A1NPC1RAB9ASMN1; SMN2MITF
SCHEMBL31017455 0.72 MAPK8 (0.34) ALDH1A1HTTNPC1RAB9ASMN1; SMN2
SCHEMBL25755354 0.69 GPR139 (0.32) GPR139
SCHEMBL25755463 0.68 ALDH1A1 (0.35) ALDH1A1HCAR3GPR139
SCHEMBL14912175 0.68 PDE10A (0.34) GPR139

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250115597-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO LTD (CN) 2025-04-10 US disclosed
US-12129250-B2 TYK2 inhibitors and compositions and methods thereof LYNK PHARMACEUTICALS CO. LTD. (CN) 2024-10-29 US disclosed
EP-4448514-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF Lynk Pharmaceuticals Co. Ltd. (CN) 2024-10-23 EP disclosed
US-20240124448-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2024-04-18 US disclosed
WO-2023109954-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2023-06-22 WO disclosed
WO-2023109954-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2023-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240124448-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF TYK2, JAK2, JAK1 ALDH1A1 4805/4885HTT 1029/4885NPC1 4269/4885
US-20250115597-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF TYK2, JAK2, JAK1 ALDH1A1 4805/4885HTT 1029/4885NPC1 4269/4885
US-12129250-B2 TYK2 inhibitors and compositions and methods thereof TYK2, JAK2, JAK1 ALDH1A1 4805/4885HTT 1029/4885NPC1 4269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.